PGENPrecigen, IncRunning, no new patients
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Papillomavirus Infections · Papillomaviridae
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jun 2024, none posted yet
Counts until it's fixed
- +1.5
5 insiders sold shares within a month
Since May 28, 2026 · was worth 10, fading over time
Worry score12
Score over time
- Stage
- Phase 1/2
- Patients
- 38 (final count)
- Started
- Mar 16, 2021
- Main results expected
- Jun 5, 2024
- Fully finished
- Jun 5, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Determine the percentage of subjects with a complete response following treatment with PRGN-2012
Measured over: 1 year
Determine the incidence of dose limiting toxicities to evaluate safety and identify RP2D of PRGN-2012
Measured over: 28 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-06-05, no fading
- insider_selling_cluster: base 10, now 1.5, since 2026-05-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04724980 · record last updated 2025-06-11 · checked 2026-11-09 15:47 UTC